SF3B1 and B-cell chronic lymphocytic leukemia: Furthermore, the SF3B1 mutation rate was higher in patients previously treated with chemotherapy than in untreated subjects, suggesting that, unlike other nonsynonymous mutations in CLL, the SF3B1 mutations could be induced or selected by chemotherapy [61].